Amendments to the Claims:

This Listing of Claims will replace all prior versions and listings of claims in the application.

Listing Of Claims
1.(canceled)
2. (canceled)
3. (canceled)
4. (previously presented) A method of treating mammary carcinoma, wherein said method comprises administering a therapeutically effective amount of octadecyl 1,1-dimethylpiperidinium-4-yl phosphate (perifosine) before and/or during treatment with an antimetabolite antitumor substance chosen from 5-fluorouracil, fludarabin, gemcitabin and cytarabin.
Claim 5. (canceled)
Claim 6. (canceled)
Claim 7. (canceled)
Claim 8 (canceled)
Claim 9 (canceled)
Claim 10 (canceled)
Claim 11 (canceled)
Claim 12. (currently amended) A drug product consisting essentially of an alkylphosphoeholine of the general Formula II as in claims 1, 3, or 4 octadecyl 1,1-dimethylpiperidinium-4-yl phosphate (perifosine) and, where appropriate, carriers and/or excipients for use in the treatment of mammary carcinoma wherein the drug product is administered before and/or

Appl. No. 10/632,187 Amdt. Dated March 3, 2011 Reply to Non-Final Office Action of September 3, 2010. Page 3 of 7

during the treatment with an approved antitumor substance chosen from 5-fluorouracil, fludarabin, gemeitabin and cytarabin.

Claim 13 (canceled)